Common Sense for Drug Policy - Link to home page

Tuesday, February 07, 2023
Search using CSDP's own search tool or use

WWW Common Sense

Home page

About CSDP

PSA Campaign

Check out these other CSDP news pages:
Anti-Drug Media Campaign
Asia and the US Drug War
Bush's Cabinet
Chronic Pain Management
Communities Against the Drug War
Conferences & Events
DARE Admits Failure
Drug Control Alternatives
Families Targeted by Drug War
Federal Drug Control Strategy
Hemp News
Heroin & Heroin Addiction Treatment
Higher Education Act (HEA) Reform
International Reform
Mandatory Minimums
Medical Marijuana
Narco-Funded Terrorism
New Mexico
New York
Pain Management
Police Shootings & Botched Raids
Prop 36
Racial Profiling
Recommended Reading
Research News
South America
Treatment Alternatives to Incarceration
United Kingdom Moves Toward Reform
United Nations: News and Reports

Drug War Facts

Research Archive

Coalition for Medical Marijuana

Managing Chronic Pain

Drug War Distortions

Safety First

Get Active!

Drug Truth Network


Drug Strategy

Drugs and Terror

Recommended Reading

Site Map

link to 
Drug War Facts - page opens in new window
in the Family

Online Drug Library

Research Resources

Contact Common Sense

Back to Oxycontin page

Maker Of Oxycontin Minimized Its Dangers In Videos For Doctors

Associated Press, Jan. 23, 2004

from the Richmond Times-Dispatch

Report Questions Claims On Drug

WASHINGTON - The maker of OxyContin sent doctors promotional videos that made unsubstantiated claims minimizing the dangers associated with the pain relief drug, congressional investigators said yesterday.

The General Accounting Office also said that in 1998, Stamford, Conn.-based Purdue Pharma failed to submit one of the videos to the Food and Drug Administration for review, as required, when the company started circulating it to thousands of doctors.

The company said its failure to send the video to the agency was an oversight. It did submit a 2001 video for FDA examination, but the agency did not review it "because of limited resources," the report said.

On the 1998 video, a doctor says less than 1 percent of people who take pain relief medication like OxyContin become addicted. That's a figure the FDA says has not been substantiated.

The FDA looked at the later video after GAO investigators inquired about it. The agency said it "appeared to make unsubstantiated claims regarding OxyContin's effect on patients' quality of life and ability to perform daily activities and minimized the risks associated with the drug."

The FDA also publicly cited Purdue Pharma last year for overstating OxyContin's safety in print ads.

OxyContin was initially hailed as a breakthrough in the treatment of severe chronic pain when it was introduced in 1996. The drug has become a problem in recent years, however, after users discovered that crushing the time-release tablets and snorting or injecting the powder yields an immediate, heroin-like high.

Lawmakers asked GAO, the investigative arm of Congress, to study Purdue Pharma's marketing of OxyContin because of the drug's widespread abuse, especially in Appalachian states.

The report said it was difficult to pinpoint the relationship between the increase of OxyContin prescriptions in recent years and the diversion of the drug to abusers.

Purdue Pharma spokesman Jim Heins said that lack of information about why the drug has been abused means critics should not point fingers at the company without obtaining more proof.

Heins confirmed that Purdue Pharma is facing roughly 340 lawsuits for its marketing of OxyContin, but he said 70 of them have been dismissed.

Save This Page to

Home Drug War Facts Public Service
Managing Chronic Pain
Get Active About Common Sense Addict In
The Family
Effective Drug
Control Strategy
Drug War Distortions Recommended

copyright © 2000-2007, Common Sense for Drug Policy
Kevin B. Zeese, President -- Mike Gray, Chairman -- Robert E. Field, Co-Chairman -- Melvin R. Allen, Board Member -- Doug McVay, Director of Research & Editor
1377-C Spencer Ave., Lancaster, PA 17603
tel 717-299-0600 - fax 717-393-4953
Updated: Thursday, July 09, 2009   ~   Accessed: 9057 times
Email us